MPMankind Pharma543904Acquisition deal news

Board approves EUR 45Mn infusion into Netherlands arm; 70% stake buy in Armed Cell Therapeutics

An additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V., raising the total limit there to EUR 50Mn, which includes the earlier EUR 5Mn.

By ScoutQuest · Thu 15 Oct 2026, 7:33 PM IST · 2 min read

Additional investment in Netherlands subsidiary

up to EUR 45Mn

Aggregate investment limit in subsidiary

EUR 50Mn

Stake acquired in Armed Cell Therapeutics B.V.

70% majority stake

Board approvals

• The board approved an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V., a wholly owned subsidiary in the Netherlands, in one or more tranches.
• This raises the aggregate investment limit in that subsidiary to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn.
• The board also approved the acquisition of a majority stake, i.e. 70%, in Armed Cell Therapeutics B.V. (ACTx) through that subsidiary.

What the money is for

• The funds will be used by the Netherlands entity to invest EUR 48Mn in ACTx, in instalments, to acquire the 70% stake.
• The consideration is cash.
• The period for completion is as per the definitive agreement.

What ACTx is

• A Belgium-incorporated biotechnology company developing next-generation armed CAR-T (chimeric antigen receptor T-cell) therapies for cancer.
• Its lead programmes target non-Hodgkin lymphoma and small cell lung cancer.
• ACTx R&D activities are led by highly experienced teams located in the US and EU. The press release names founders including Dr. Paul Stoffels, Chair of the Board and formerly CEO of Galapagos and Chief Scientific Officer of Johnson & Johnson, and Dr. John Mellors, Chief Scientific Officer.

Structure and related-party points

• Mankind Netherlands is an existing wholly owned subsidiary, incorporated on August 13, 2026, with the business objective of holding investments in R&D assets and business development in niche therapies; its turnover is Nil.
• ACTx authorised share capital is EUR 50Mn and paid-up share capital is EUR 0.02Mn; its turnover is Nil.
• The investment by the company into Mankind Netherlands is a related party transaction, as that entity is a wholly owned subsidiary; the investment in ACTx by the Netherlands entity is not a related party transaction.
• The investment in Mankind Netherlands will not cause any change in the percentage of the shareholding of the company, which will continue to remain a wholly owned subsidiary.

How the company frames it

• The update describes the investment as part of the company's long-term strategy to build a global innovation-led pharmaceutical business.
• The press release is titled "Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies" and states the transaction was entered into under a definitive agreement.
• The press release carries a safe harbour statement covering forward-looking statements.

For reference, the press release describes Mankind Pharma as one of the largest pharmaceutical companies in India, with a field force of 18,500+ professionals reaching over five lakh doctors, 32 manufacturing facilities in India and 7 dedicated R&D facilities backed by more than 740 scientists.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev